News

News 27.10.2025 ZURICH, Switzerland--(BUSINESS WIRE)--CDR-Life, Inc., a biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, today announced the first clinical data showing that CDR404, the company’s lead M-gager® TCE, achieved all four canonical pharmacodynamic (PD) hallmarks of TCE activity in patients with MAGE-A4+ solid tumors. The...

News 23.10.2025 Schlieren, Switzerland and Washington, D.C. — The Schlieren-based biotech company InSphero is presenting the HUMAIN Award for the second time this year, in collaboration with the Physicians Committee for Responsible Medicine. The five winning teams are from Switzerland, Portugal, the United States, Spain, and Germany. According to a press release, InSphero...

News 21.10.2025 Schlieren, Switzerland, October 20, 2025 – ImmunOs Therapeutics AG, a clinical-stage biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases, today announced encouraging preliminary results from its ongoing Phase I clinical trial evaluating IOS-1002 in patients with advanced...

News 16.10.2025 Financial & Operational Highlights Total Medical Device sales rose by 77% to USD 101.1 million for the first nine months of 2025 (9M 2024: USD 57.2 million) Direct MagnetOs™ sales increased by 76% to USD 99.7 million for the first nine months of 2025 (9M 2024: USD 56.7 million) EBITDA...

News 15.10.2025 Zurich, Switzerland - 14.10.2025 Neurimmune today announced it has initiated a Phase 2 follow-on study to evaluate the pharmacodynamics and safety of cliramitug (formerly ALXN2220, NI006) for transthyretin amyloid cardiomyopathy (ATTR-CM) in patients who were previously enrolled in the proof-of-concept study NI006-101 (NCT04360434). Cliramitug is an investigational human monoclonal antibody designed to...